A phase III, multicentre, prospective, randomized double-blind study comparing intraocular pressure lowering efficacy of preservative-free fixed and non-fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with pseudoexfoliative glaucoma (XFG).

Trial Profile

A phase III, multicentre, prospective, randomized double-blind study comparing intraocular pressure lowering efficacy of preservative-free fixed and non-fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with pseudoexfoliative glaucoma (XFG).

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2015

At a glance

  • Drugs Tafluprost/timolol (Primary) ; Tafluprost; Timolol
  • Indications Glaucoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top